Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Post by edroseon Jul 20, 2021 4:46pm
107 Views
Post# 33576737

Consonance and armitage sold all their shares at loss becaus

Consonance and armitage sold all their shares at loss becaus

They also saw it coming.  

1- gave plasma division away two weeks before fda approval 
2-tell investors we will put efforts re small molecules ie 4050 and analogs  then out of the bluehalt all studies because PK DATA IS BAD. Then refuse to release info 

look at 4050 previous study results they are very good alstrom results show excellent response in different organs     At 800 mg per day 

prometic scientist like laurin,Lynne gagnon and her team John Moran never raised issues re pk data that would be so bad to halt studies 

THEY ARE BUYING TIME TO CONTINUE THEIR PLAN

<< Previous
Bullboard Posts
Next >>